THE WOODLANDS, Texas
Oct. 17, 2012
/PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it commenced an offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Lexicon. J.P. Morgan Securities LLC and Jefferies & Company, Inc. will be acting as joint book-runners for the offering.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. The offering of these securities will be made only by means of a preliminary prospectus supplement and accompanying prospectus, copies of which may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York
11717, or by telephone at 866-803-9204, or from Jefferies & Company, Inc. at 520 Madison Avenue, 12th Floor,
New York, NY
, 10022, Attention: Equity Syndicate Prospectus Department, by calling (877) 547-6340 or by emailing
The issuer has on file with the Securities and Exchange Commission, or SEC, an effective registration statement (including a base prospectus) on Form S-3 for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at
. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.